drugset
drugset / Trial / NCT05244759

Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937

NCT05244759 ↗

Phase 1 Completed 6 enrolled Bellus Health Inc. - a GSK company
NaSingle-groupOpen-labelTreatment

Summary

This is a single-centre, open-label, non-randomised, single-period, single-dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification of \[14C\]-BLU-5937.

Timeline

Start
2020-08-25
Primary completion
2020-09-23
Completion
2021-03-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Camlipixant Small molecule — Oral

Indications

No indication recorded.